263 related articles for article (PubMed ID: 34307344)
21. Gene amplification-driven RNA methyltransferase KIAA1429 promotes tumorigenesis by regulating BTG2 via m6A-YTHDF2-dependent in lung adenocarcinoma.
Zhang C; Sun Q; Zhang X; Qin N; Pu Z; Gu Y; Yan C; Zhu M; Dai J; Wang C; Li N; Jin G; Ma H; Hu Z; Zhang E; Tan F; Shen H
Cancer Commun (Lond); 2022 Jul; 42(7):609-626. PubMed ID: 35730068
[TBL] [Abstract][Full Text] [Related]
22. N6-Methyladenosine Modification Patterns and Tumor Microenvironment Immune Characteristics Associated With Clinical Prognosis Analysis in Stomach Adenocarcinoma.
Meijing Z; Tianhang L; Biao Y
Front Cell Dev Biol; 2022; 10():913307. PubMed ID: 35813200
[No Abstract] [Full Text] [Related]
23. A Novel m6A-Related LncRNA Signature for Predicting Prognosis, Chemotherapy and Immunotherapy Response in Patients with Lung Adenocarcinoma.
Shen Y; Wang S; Wu Y
Cells; 2022 Aug; 11(15):. PubMed ID: 35954243
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive Analysis of Tumor Immune Microenvironment and Prognosis of m6A-Related IncRNAs in Lung Adenocarcinoma.
Shen Y; Hou N; Han F; Chen B; Shi J; Sun X
Crit Rev Eukaryot Gene Expr; 2022; 32(5):77-91. PubMed ID: 35993946
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive Analysis Revealed the Potential Implications of m6A Regulators in Lung Adenocarcinoma.
Xie L; Dai R; Wang X; Xie G; Gao Z; Xu X
Front Mol Biosci; 2022; 9():806780. PubMed ID: 35419413
[No Abstract] [Full Text] [Related]
26. A five-m6A regulatory gene signature is a prognostic biomarker in lung adenocarcinoma patients.
Wu X; Sheng H; Wang L; Xia P; Wang Y; Yu L; Lv W; Hu J
Aging (Albany NY); 2021 Mar; 13(7):10034-10057. PubMed ID: 33795529
[TBL] [Abstract][Full Text] [Related]
27. Link between m6A modification and infiltration characterization of tumor microenvironment in lung adenocarcinoma.
Yang S; Li K; Zhang J; Liu J; Liu L; Tan Y; Xu C
Exp Biol Med (Maywood); 2023 Dec; 248(23):2273-2288. PubMed ID: 38166412
[TBL] [Abstract][Full Text] [Related]
28. Prognostic Impact of
Guo W; Huai Q; Wan H; Guo L; Song P; Gao S; He J
DNA Cell Biol; 2021 Feb; 40(2):316-331. PubMed ID: 33493403
[TBL] [Abstract][Full Text] [Related]
29. Upregulation of M6A Reader HNRNPA2B1 Associated with Poor Prognosis and Tumor Progression in Lung Adenocarcinoma.
Wang W; Li S
Recent Pat Anticancer Drug Discov; 2023 Oct; ():. PubMed ID: 37877146
[TBL] [Abstract][Full Text] [Related]
30. N6-Methylandenosine-Related lncRNAs Predict Prognosis and Immunotherapy Response in Bladder Cancer.
Zhang Y; Zhu B; He M; Cai Y; Ying X; Jiang C; Ji W; Zeng J
Front Oncol; 2021; 11():710767. PubMed ID: 34458149
[TBL] [Abstract][Full Text] [Related]
31. N6-methyladenosine-regulated ADIRF impairs lung adenocarcinoma metastasis and serves as a potential prognostic biomarker.
Teng Y; Zhao X; Xi Y; Fu N
Cancer Biol Ther; 2023 Dec; 24(1):2249173. PubMed ID: 37700507
[TBL] [Abstract][Full Text] [Related]
32. Potential impact of WTAP and YTHDF2 on tumor immunity in lung adenocarcinoma.
Zhang X; Cai X
Medicine (Baltimore); 2022 Nov; 101(45):e31195. PubMed ID: 36397411
[TBL] [Abstract][Full Text] [Related]
33. Glycolysis Define Two Prognostic Subgroups of Lung Adenocarcinoma With Different Mutation Characteristics and Immune Infiltration Signatures.
Huo C; Zhang MY; Li R; Liu TT; Li JP; Qu YQ
Front Cell Dev Biol; 2021; 9():645482. PubMed ID: 34368114
[TBL] [Abstract][Full Text] [Related]
34. CD1B is a Potential Prognostic Biomarker Associated with Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Adenocarcinoma.
Li Z; Feng Y; Li P; Wang S; Liu X; Xia S
Int J Gen Med; 2022; 15():3809-3826. PubMed ID: 35418778
[TBL] [Abstract][Full Text] [Related]
35. Development and Validation of a Prognostic N6-Methyladenosine-Related Immune Gene Signature for Lung Adenocarcinoma.
Zhang L; Luo Y; Cheng T; Chen J; Yang H; Wen X; Jiang Z; Li H; Pan C
Pharmgenomics Pers Med; 2021; 14():1549-1563. PubMed ID: 34876833
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive Analysis for Predicting Prognoses and Immune Responses of m6A-Related lncRNAs in Women with Lung Adenocarcinoma.
Wu S; Tu Q; Yuan H; Wu Z; Yang Y; Chen C; Huang C
Biochem Genet; 2023 Nov; ():. PubMed ID: 37999876
[TBL] [Abstract][Full Text] [Related]
37. N6-Methyladenosine Regulators Promote Malignant Progression of Gastric Adenocarcinoma.
Zhao Y; Yan X; Wang Y; Zhou J; Yu Y
Front Oncol; 2021; 11():726018. PubMed ID: 35299934
[TBL] [Abstract][Full Text] [Related]
38. DUSP5 regulated by YTHDF1-mediated m6A modification promotes epithelial-mesenchymal transition and EGFR-TKI resistance via the TGF-β/Smad signaling pathway in lung adenocarcinoma.
Fan W; Xing Y; Yan S; Liu W; Ning J; Tian F; Wang X; Zhan Y; Luo L; Cao M; Huang J; Cai L
Cancer Cell Int; 2024 Jun; 24(1):208. PubMed ID: 38872157
[TBL] [Abstract][Full Text] [Related]
39. Construction of a risk prediction model using m6A RNA methylation regulators in prostate cancer: comprehensive bioinformatic analysis and histological validation.
Quan Y; Zhang X; Ping H
Cancer Cell Int; 2022 Jan; 22(1):33. PubMed ID: 35045837
[TBL] [Abstract][Full Text] [Related]
40. Target genes of N6-methyladenosine regulatory protein
Jiang L; Lan L; Qiu Y; Lu W; Wang W; Huang Y
J Thorac Dis; 2023 Jun; 15(6):3228-3236. PubMed ID: 37426138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
